详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Editorial: Predictive short/long-term efficacy biomarkers and resistance mechanisms of CAR-T immunotherapy treatment

70| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.

出处：

DOI：

ISSN：

关键词： chimeric antigen receptor-T cell therapy efficacy biomarkers tumor characteristics CAR-T cell characteristics immune conditions

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2021]版：

Q1 IMMUNOLOGY

最新[2024]版：

Q1 IMMUNOLOGY

影响因子： 5.9 最新[2024版] 6.8 最新五年平均 8.787 出版当年[2021版] 8.877 出版当年五年平均 7.561 出版前一年[2020版] 7.3 出版后一年[2022版]

第一作者：

第一作者单位： [1]Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.

通讯作者：

通讯机构： [1]Department of Hematology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies [2]Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [3]Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study [4]Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy [5]Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30(+) lymphoma patients [6]The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook [7]Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future [8]Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for CD30+ Relapsed/Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients [9]药师在嵌合抗原受体t细胞治疗中的职责和工作探究 [10]Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract